Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

Recent years have seen a 12 percent decline in new HIV infections. Cuts to federal funding could upend that progress.

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are targeting the next goalpost: a cure.

Mike McCune, MD, PhD, head of the HIV Frontiers Program at the Gates Foundation, delivered an upbeat message at the ASGCT annual conference in New Orleans last week, showcasing the progress being made ...

Nika Pharmaceuticals, Inc. (OTCQB: NIKA) presents projected revenue for each market with exclusive distribution agreement.

No significant association was observed between viremia history during ART and CVD risk in a large international cohort of patients with HIV infection.

A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based ...

The health center Vivent Health+TPAN, located at 5537 N. Broadway, is providing clinical care in collaboration with ...

Bush’s priorities. Africa’s most populous nation had 3.5 million HIV cases, and the disease threatened to destabilize the region and ultimately compromise U.S. interests. These interests included ...

Ukraine relies on the U.S. to fund HIV services during the war. The Trump administration is still mulling axing its support.

“It would be really helpful if the ministry acknowledged the gaps created and articulated a plan to ensure the gap will be filled at least partially." HIV treatment and prevention is one of the ...